PMID- 26238598
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20210109
IS  - 1557-0657 (Electronic)
IS  - 1049-8931 (Print)
IS  - 1049-8931 (Linking)
VI  - 25
IP  - 2
DP  - 2016 Jun
TI  - Defining the minimal clinically important difference (MCID) of the 
      Heinrichs-carpenter quality of life scale (QLS).
PG  - 101-11
LID - 10.1002/mpr.1483 [doi]
AB  - To determine the Minimal Clinically Important Difference (MCID) of the 
      Heinrichs-Carpenter Quality of Life Scale (QLS). Data from the "Schizophrenia 
      Trial of Aripiprazole" (STAR) study were used in this analysis. The MCID value of 
      the QLS total score was estimated using the anchor-based method. These findings 
      were substantiated/validated by comparing the MCID estimate to other measurements 
      collected in the study. Half of the patients (49%) showed improvement in Clinical 
      Global Impressions of Severity (CGI-S) during the trial. The estimated MCID of 
      the QLS total score was 5.30 (standard error: 2.60; 95% confidence interval: 
      [0.16; 10.43]; p < 0.05). Patients were divided into two groups: "QLS improvers" 
      (QLS total score increased >/= six points) and "non-improvers". The QLS improvers 
      had significantly better effectiveness and reported significantly higher levels 
      of preference for their current medications. There was a statistically 
      significant difference between the two groups in the change in two of the four 
      domains of QLS; "Interpersonal relations" and "Intrapsychic foundations" domains 
      during the study. These findings support the value of the estimated MCID for the 
      QLS and may be a useful tool in evaluating antipsychotic treatment effects and 
      improving long-term patient outcomes in schizophrenia. Copyright (c) 2015 John 
      Wiley & Sons, Ltd.
CI  - Copyright (c) 2015 John Wiley & Sons, Ltd.
FAU - Falissard, Bruno
AU  - Falissard B
AD  - INSERM U669, Universite Paris-Sud and Universite Paris-Descartes, APHP, Paris, 
      France.
FAU - Sapin, Christophe
AU  - Sapin C
AD  - Global Analytics, Lundbeck SAS, Issy-les-Moulineaux, France.
FAU - Loze, Jean-Yves
AU  - Loze JY
AD  - Otsuka Pharmaceutical Europe Ltd, Paris, France.
FAU - Landsberg, Wally
AU  - Landsberg W
AD  - Otsuka Pharmaceutical Europe Ltd, London, UK.
FAU - Hansen, Karina
AU  - Hansen K
AD  - Global Health Economics and Epidemiology, Lundbeck SAS, Issy-les-Moulineaux, 
      France.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150804
PL  - United States
TA  - Int J Methods Psychiatr Res
JT  - International journal of methods in psychiatric research
JID - 9111433
RN  - 0 (Antipsychotic Agents)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*pharmacology
MH  - Aripiprazole/*pharmacology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - *Psychiatric Status Rating Scales
MH  - *Quality of Life
MH  - Schizophrenia/*drug therapy
PMC - PMC6877136
OTO - NOTNLM
OT  - Minimal Clinically Important Difference
OT  - Quality of Life Scale
OT  - schizophrenia
EDAT- 2015/08/05 06:00
MHDA- 2018/01/18 06:00
PMCR- 2015/08/04
CRDT- 2015/08/05 06:00
PHST- 2014/09/22 00:00 [received]
PHST- 2015/02/12 00:00 [revised]
PHST- 2015/04/23 00:00 [accepted]
PHST- 2015/08/05 06:00 [entrez]
PHST- 2015/08/05 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2015/08/04 00:00 [pmc-release]
AID - MPR1483 [pii]
AID - 10.1002/mpr.1483 [doi]
PST - ppublish
SO  - Int J Methods Psychiatr Res. 2016 Jun;25(2):101-11. doi: 10.1002/mpr.1483. Epub 
      2015 Aug 4.